Neurocrine biosciences presents new post-hoc data analyses from kinect®-hd study demonstrating significant reduction in disease burden with ingrezza® (valbenazine) capsules for huntington's disease chorea

Patient-reported analyses demonstrated greater reduction in both cognitive and motor-related disease burden for ingrezza compared with placebo findings to be presented at the 2025 advanced therapeutics in movement & related disorders (atmrd) congress san diego , june 27, 2025 /prnewswire/ -- neurocrine biosciences, inc. (nasdaq: nbix) today announced new patient-reported post-hoc data from the kinect®-hd study highlighting significant reductions in both cognitive and motor-related burdens among adults treated for huntington's disease chorea with once-daily ingrezza® (valbenazine) capsules. kinect-hd is the first and only clinical study to demonstrate measurable changes in cognitive and motor disease burden with a vesicular monoamine transporter 2 inhibitor (ingrezza) in patients treated for chorea.
NBIX Ratings Summary
NBIX Quant Ranking